Skip to main content
. 2023 Feb 8;15(2):570. doi: 10.3390/pharmaceutics15020570

Figure 2.

Figure 2

Drugs that target dysfunctional mitochondrial processes in kidney diseases. Szeto–Schiller peptide 20, SS-31: Szeto–Schiller peptide 31, Mdivi-1: mitochondrial division inhibitor 1, TDZD-8: 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione, SkQs: plastoquinone, CoQ10: coenzyme Q10, mTOR: mammalian target of rapamycin, GLP-1-RA: glucagon-like peptide-1 receptor agonists, SGLT-2: sodium glucose co-transporter-2, DPP-4: dipeptidyl peptidase 4, SI-AKI: sepsis-induced acute kidney injury, IR-AKI: ischemia/reperfusion-induced acute kidney injury, CisI-AKI: cisplatin-induced acute kidney injury, CI-AKI: contrast-induced acute kidney injury, NSAID-AKI: non-steroidal anti-inflammatory drug-induced acute kidney injury, Genta-AKI: gentamicin-induced acute kidney injury, RAS: renal artery stenosis, UUO: unilateral ureteral obstruction, DKD: diabetic kidney disease, CKD: chronic kidney disease, ADPKD: autosomal dominant polycystic kidney disease.